October 27, 2023
Written by Natalia Muehlemann, Vice President, Clinical Development; Martin Frenzel, Research Principal, Statistical...
Read article
April 24, 2023
In the last 10 years, the Asia-Pacific (APAC) region has become a hotspot for clinical trials: the region contributed...
Read article
November 18, 2022
In the following interview, Dr. Parvin Fardipour, Quantitative Strategies & Data Science, sits down with Heather...
Read article
August 26, 2022
To continue our Summer Weekend Reads series, Cytel presents “Discover the Value of an Optimized Clinical Data Strategy”...
Read article
May 16, 2022
A combination of industry and policy forces have recently changed the shape of Australia’s R&D sector, making it a...
Read article
June 25, 2021
The main challenge associated with the development of therapies for rare diseases is typically the small study sample...
Read article
June 4, 2021
Bayesian methods have been playing a key role in transforming clinical research in therapeutic areas such as oncology...
Read article
June 28, 2018
By Esha Senchaudhuri With thanks also to Jitendarreddy Seelam and Ramanatha Saralaya for their input. The fact of the...
Read article
February 9, 2017
In this blog, Adam Hamm, PhD, Director Biostatistics at Cytel shares some of the most important knowledge he uses in...
Read article
May 10, 2016
We were fortunate to welcome Björn Bornkamp of Novartis to the EUGM 2016 presenting work he has developed jointly with...
Read article
April 22, 2016
FDA draft guidance on “Co development of two or more unmarketed investigational drugs for use in combination” notes...
Read article
April 7, 2016
Francois Beckers, Global Head of Biostatistics & Epidemiology at Merck KGaA joined us at the East User Group Meeting in...
Read article
March 29, 2016
On March 16th and 17th the 5th East User Group Meeting took place in London. This very successful 2 days saw a variety...
Read article
November 12, 2015
Last week Cytel joined forces with Sanofi/Genzyme to devote a full day of workshops and talks related to modern methods...
Read article
October 19, 2015
It is often necessary to pool safety data from late phase studies, in preparation for regulatory submission. Some of...
Read article
September 4, 2015
Our Client's Challenge: Can knowledge of the relationship between biomarkers and clinical endpoints help us to optimize...
Read article
September 1, 2015
If you’re in the practice of conducting early phase clinical trials, you’ve probably heard that modern trial designs...
Read article
August 10, 2015
When approaching a Phase 3 clinical trial, the need to ‘de-risk’ the massive investment often leads sponsors on a quest...
Read article
May 20, 2015
Seamless adaptive clinical trials have gained popularity for reducing the projected time it takes to complete the...
Read article
April 23, 2015
Last week the Cytel Blog discussed the benefits of using the Adaptive Maximizing Design [AM Design] for dose-finding...
Read article
January 22, 2015
The Journal of the American Medical Association recently published an article entitled ‘The Anatomy of Medical...
Read article
January 20, 2015
According to a recent Cytel Whitepaper on Adaptive Clinical Trials, 50% of Phase 3 trials eventually fail. This new...
Read article
December 18, 2014
Earlier this week, we at Cytel enjoyed a riveting in-house discussion on the uses of Bayesian decision rules for...
Read article
November 18, 2014
Statisticians and scientists at Novartis have been at the forefront of developing a new method in early phase oncology...
Read article
